Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that President and CEO Bo Rode Hansen by mutual agreement will leave his position with immediate effect.
Johnny Stilou, who has been employed by Scandion as Chief Financial Officer since July 2021, has been appointed acting CEO effective immediately. The process to identify a new permanent CEO has started.
Bo Rode Hansen will also step down as a member of the Board of Directors of Scandion with immediate effect.
”I am proud of what I and the whole team have accomplished during these last two years since I joined. Scandion is a very different company today compared to when I took over as CEO. It is time for me to move on to new endeavors, and I wish all the best for Scandion in the future”, says Bo Rode Hansen.
“The Board wishes Bo Rode Hansen best of luck as he pursues new opportunities. We have initiated the process to identify a new CEO for Scandion with the right qualifications and experience. The team remains focused on delivering on the operational priorities of the company”, says Martin Møller, Chairman of the Board of Directors.
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 31, 2022, at 11.45 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.